• Minoryx completed enrollment in the global Phase 3 CALYX trial of leriglitazone (NEZGLYAL®) for adult male cerebral adrenoleukodystrophy.
• Neuraxpharm is preparing a European launch as EU approval under exceptional circumstances is expected later this month.
• Leriglitazone received a positive CHMP opinion in Europe for boys aged 2-12 with cALD and non-gadolinium enhancing lesions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pappas Capital LLC published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.